Compare Nvidia Corp (NVDA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs TG Therapeutics Inc — how do they compare? Nvidia Corp trades at $222.9 (market cap $5.40T), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Nvidia Corp is far larger — about 645.9× TG Therapeutics Inc's market cap, and Nvidia Corp pays a 0.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NVDA | TGTX | |
|---|---|---|
Market Cap | $5.40T | $8.36B |
Sector | Technology | Health |
52-Week High | $235.75 | $59.06 |
52-Week Low | $165.17 | $26.94 |
Enterprise Value | $5.38T | $8.57B |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $225.73, down 2.01% today, with a bullish technical signal from moving averages and support near $222. The company reported robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.47. Revenue surged to $130.50B in 2025, driving a net income margin of 63.66%, while valuation ratios like P/E of 28.54 reflect high growth expectations. Analysts maintain strong buy consensus amid AI-driven demand.
Outlook remains positive due to AI leadership and accelerating revenue, but risks include competition and market volatility. The stock offers significant upside to the $344.10 consensus target, though investors should monitor execution risks and macroeconomic headwinds.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
